Document Detail

Effects of cardiopulmonary bypass on sufentanil pharmacokinetics in patients undergoing coronary artery bypass surgery.
MedLine Citation:
PMID:  15448518     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Complete pharmacokinetic modeling, including assessment of the effect of cardiopulmonary bypass (CPB) on sufentanil disposition, has not been reported. The aims of this investigation were to define a model that accurately predicted sufentanil concentrations during and after cardiac surgery and to determine if CPB had a clinically significant impact on sufentanil pharmacokinetics. METHODS: Population pharmacokinetic modeling was applied to data from 21 patients undergoing coronary artery bypass grafting. The predictive ability of models was assessed by calculating bias, accuracy, and measured:predicted concentration ratios versus time. A simple three-compartment model, without covariates, was initially compared with models having weight or gender as covariates and was subsequently used as the foundation for multiple CPB-adjusted models (allowing step-changes of parameters at the start or end of CPB). The primary criterion for choosing more complex models was a significant improvement in log-likelihood; secondary criteria were significant improvement in bias or accuracy. RESULTS: Neither covariate (weight or gender) models improved bias or accuracy compared with the simple three-compartment model. A final CPB-adjusted model with V2 and Cl3 changing at the start of CPB and V1, Cl2, and Cl3 changing at the end of CPB had significantly greater log-likelihood values when compared with the simple three-compartment model and with less elaborate CPB-adjusted models. However, bias and accuracy for this final model were not significantly different from the simple three-compartment model. CONCLUSIONS: When sufentanil is infused at a constant rate, with initiation of CPB, a pharmacokinetic model adjusted for CPB predicts that the sufentanil concentration will decrease approximately 17% and that it will begin to return to the prebypass concentration 12 min after initiation of CPB. At the end of CPB, this model also predicts a brief spike of the sufentanil concentration. These predictions reflect changes in the measured sufentanil concentrations. However, compared with a simple, three-compartment model, incorporating step-changes of pharmacokinetic parameters at the start or end of cardiopulmonary bypass (or both) did not significantly improve overall perioperative prediction of measured sufentanil concentrations. This suggests that CPB has clinically insignificant effects on sufentanil kinetics in adults.
Robert J Hudson; Ian R Thomson; Rajive Jassal
Related Documents :
15616298 - Pharmacodynamic modeling of ciprofloxacin resistance in staphylococcus aureus.
10858338 - A population pharmacokinetic analysis of nelfinavir mesylate in human immunodeficiency ...
20176408 - Pksolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in mi...
7859808 - Pharmacokinetic analysis of sparse in vivo nmr spectroscopy data using relative paramet...
20585458 - A lagrangian identification of the main sources of moisture affecting northeastern braz...
2722508 - A microcomputer algorithm for solving first-order compartmental models involving recycl...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Anesthesiology     Volume:  101     ISSN:  0003-3022     ISO Abbreviation:  Anesthesiology     Publication Date:  2004 Oct 
Date Detail:
Created Date:  2004-09-27     Completed Date:  2004-10-19     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  1300217     Medline TA:  Anesthesiology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  862-71     Citation Subset:  AIM; IM    
Department of Anesthesia, St. Boniface General Hospital, University of Manitoba, Winnipeg, Manitoba, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cardiopulmonary Bypass*
Coronary Artery Bypass*
Middle Aged
Models, Biological
Sufentanil / pharmacokinetics*
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Apolipoprotein E genotype and cognitive dysfunction after noncardiac surgery.
Next Document:  Do indomethacin and propofol cause cerebral ischemic damage? Diffusion-weighted magnetic resonance i...